NASDAQ:CORI - Corium International Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$8.20 -0.04 (-0.49 %)
(As of 05/24/2018 07:47 AM ET)
Previous Close$8.24
Today's Range$8.10 - $8.45
52-Week Range$6.25 - $13.93
Volume478,072 shs
Average Volume277,361 shs
Market Capitalization$297.79 million
P/E Ratio-5.00
Dividend YieldN/A
Beta1.61

About Corium International (NASDAQ:CORI)

Corium International logoCorium International, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of specialty pharmaceutical products in transdermal and transmucosal delivery systems. It offers Clonidine Transdermal Delivery System (TDS), a treatment for hypertension; Fentanyl TDS, a treatment for the management of chronic pain, including cancer-related pain; and Crest Whitestrips for teeth whitening. The company's products under pipeline comprise Twirla, a combination hormonal contraceptive patch, which has completed Phase III clinical trials to deliver ethinyl estradiol and levonorgestrel hormones; MicroCor hPTH(1-34), a transdermal system that has completed Phase 1 and Phase II a clinical trials for the treatment of severe osteoporosis; and Donepezil and Memantine transdermal systems, which completed Phase I clinical trials for the treatment of Alzheimer's disease. In addition, it develops Aripiprazole TDS for the treatment for psychiatric disorders; Corplex Ropinirole, a transdermal patch for the treatment of Parkinson's disease; and Motion Sickness Patch, a generic transdermal product for the prevention of nausea and vomiting associated with motion sickness. Corium International, Inc. has collaboration agreements with The Procter & Gamble Company; Teva Pharmaceuticals USA, Inc.; Agile Therapeutics, Inc.; and Aequus Pharmaceuticals, Inc. The company was incorporated in 1995 and is headquartered in Menlo Park, California.

Receive CORI News and Ratings via Email

Sign-up to receive the latest news and ratings for CORI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CORI
CUSIPN/A
Phone650-298-8012

Debt

Debt-to-Equity Ratio1.89
Current Ratio8.11
Quick Ratio7.95

Price-To-Earnings

Trailing P/E Ratio-5.00
Forward P/E Ratio-5.36
P/E GrowthN/A

Sales & Book Value

Annual Sales$31.86 million
Price / Sales9.30
Cash FlowN/A
Price / CashN/A
Book Value$1.00 per share
Price / Book8.20

Profitability

EPS (Most Recent Fiscal Year)($1.64)
Net Income$-47,790,000.00
Net Margins-156.05%
Return on Equity-273.01%
Return on Assets-61.11%

Miscellaneous

Employees213
Outstanding Shares36,140,000

Corium International (NASDAQ:CORI) Frequently Asked Questions

What is Corium International's stock symbol?

Corium International trades on the NASDAQ under the ticker symbol "CORI."

How were Corium International's earnings last quarter?

Corium International Inc (NASDAQ:CORI) issued its quarterly earnings results on Monday, May, 14th. The biopharmaceutical company reported ($0.43) EPS for the quarter, missing analysts' consensus estimates of ($0.39) by $0.04. The biopharmaceutical company earned $10.06 million during the quarter, compared to the consensus estimate of $7.07 million. Corium International had a negative net margin of 156.05% and a negative return on equity of 273.01%. View Corium International's Earnings History.

What price target have analysts set for CORI?

5 Wall Street analysts have issued 1-year price objectives for Corium International's shares. Their forecasts range from $10.00 to $14.00. On average, they expect Corium International's stock price to reach $13.00 in the next twelve months. View Analyst Ratings for Corium International.

What are Wall Street analysts saying about Corium International stock?

Here are some recent quotes from research analysts about Corium International stock:
  • 1. Cantor Fitzgerald analysts commented, "Our CORI , 2019E — — — — REV 1Q 2Q 3Q 4Q 2017A 7.0A 7.3A 8.1A 9.4A 2018E 9.3A 10.1A 8.0E 8.0E 2019E — — — —." (5/18/2018)
  • 2. According to Zacks Investment Research, "Corium International, Inc. is a commercial-stage biopharmaceutical company. It is focused on the development, manufacture and commercialization of specialty pharmaceutical products that leverage advanced technologies in transdermal and transmucosal delivery systems. Corium has developed six marketed products in the prescription drug and consumer markets: Clonidine Transdermal Delivery System for hypertension, Fentanyl TDS for chronic pain and four Crest Advanced Seal Whitestrips products. The company has two proprietary transdermal technology platforms with applications in multiple drug categories and indications: Corplex(TM) and MicroCor(R). Corium International, Inc. is headquartered in Menlo Park, California. " (5/17/2018)

Who are some of Corium International's key competitors?

Who are Corium International's key executives?

Corium International's management team includes the folowing people:
  • Mr. Peter D. Staple, Pres, CEO & Director (Age 66)
  • Mr. Robert S. Breuil, Chief Financial Officer (Age 56)
  • Dr. Parminder Singh, CTO & VP of R&D (Age 54)
  • Mr. Timothy D. Sweemer CPA, Chief Accounting Officer, VP of Admin. & Sec.
  • Ms. Christina Dickerson, VP of Corp. Devel.

Has Corium International been receiving favorable news coverage?

Headlines about CORI stock have been trending somewhat negative this week, Accern Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Corium International earned a media sentiment score of -0.13 on Accern's scale. They also gave headlines about the biopharmaceutical company an impact score of 46.74 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.

Who are Corium International's major shareholders?

Corium International's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Franklin Resources Inc. (5.70%), RIDGEBACK CAPITAL INVESTMENTS L.P. (5.20%), BlackRock Inc. (5.21%), Tamarack Advisers LP (3.06%), Northern Trust Corp (0.67%) and Needham Investment Management LLC (0.62%). Company insiders that own Corium International stock include Healthcare Master Fun Broadfin, Joseph J Sarret, Life Sciences Maste Perceptive, Parminder Singh, Perceptive Advisors Llc and Timothy D Sweemer. View Institutional Ownership Trends for Corium International.

Which institutional investors are selling Corium International stock?

CORI stock was sold by a variety of institutional investors in the last quarter, including Needham Investment Management LLC, Northern Trust Corp, Schwab Charles Investment Management Inc. and California State Teachers Retirement System. Company insiders that have sold Corium International company stock in the last year include Healthcare Master Fun Broadfin, Joseph J Sarret, Parminder Singh and Timothy D Sweemer. View Insider Buying and Selling for Corium International.

Which institutional investors are buying Corium International stock?

CORI stock was purchased by a variety of institutional investors in the last quarter, including Franklin Resources Inc., BlackRock Inc., Candriam Luxembourg S.C.A., Tamarack Advisers LP, JPMorgan Chase & Co., Citadel Advisors LLC, Iguana Healthcare Management LLC and DekaBank Deutsche Girozentrale. Company insiders that have bought Corium International stock in the last two years include Life Sciences Maste Perceptive and Perceptive Advisors Llc. View Insider Buying and Selling for Corium International.

How do I buy shares of Corium International?

Shares of CORI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Corium International's stock price today?

One share of CORI stock can currently be purchased for approximately $8.20.

How big of a company is Corium International?

Corium International has a market capitalization of $297.79 million and generates $31.86 million in revenue each year. The biopharmaceutical company earns $-47,790,000.00 in net income (profit) each year or ($1.64) on an earnings per share basis. Corium International employs 213 workers across the globe.

How can I contact Corium International?

Corium International's mailing address is 235 CONSTITUTION DRIVE, MENLO PARK CA, 94025. The biopharmaceutical company can be reached via phone at 650-298-8012 or via email at [email protected]


MarketBeat Community Rating for Corium International (CORI)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  263 (Vote Outperform)
Underperform Votes:  187 (Vote Underperform)
Total Votes:  450
MarketBeat's community ratings are surveys of what our community members think about Corium International and other stocks. Vote "Outperform" if you believe CORI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CORI will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Corium International (NASDAQ:CORI) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
5 Wall Street analysts have issued ratings and price targets for Corium International in the last 12 months. Their average twelve-month price target is $13.00, suggesting that the stock has a possible upside of 58.54%. The high price target for CORI is $14.00 and the low price target for CORI is $10.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $13.00$13.00$13.00$13.1667
Price Target Upside: 58.54% upside21.16% upside8.70% upside15.19% upside

Corium International (NASDAQ:CORI) Consensus Price Target History

Price Target History for Corium International (NASDAQ:CORI)

Corium International (NASDAQ:CORI) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/18/2018Cantor FitzgeraldReiterated RatingBuy$14.00LowView Rating Details
5/15/2018HC WainwrightSet Price TargetBuy$14.00HighView Rating Details
12/26/2017Needham & Company LLCLower Price TargetBuy ➝ Buy$16.00 ➝ $14.00HighView Rating Details
10/29/2017Jefferies GroupSet Price TargetBuy$10.00N/AView Rating Details
7/7/2017WBB SecuritiesUpgradeBuy$13.00LowView Rating Details
4/18/2017FBR & CoReiterated RatingOutperform ➝ Outperform$12.00 ➝ $13.00LowView Rating Details
1/4/2017Leerink SwannReiterated RatingBuyN/AView Rating Details
(Data available from 5/24/2016 forward)

Earnings

Corium International (NASDAQ:CORI) Earnings History and Estimates Chart

Earnings by Quarter for Corium International (NASDAQ:CORI)

Corium International (NASDAQ:CORI) Earnings Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q3 20181($0.33)($0.33)($0.33)
Q4 20181($0.32)($0.32)($0.32)

Corium International (NASDAQ CORI) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/14/2018Q2 2018($0.39)($0.43)$7.07 million$10.06 millionViewListenView Earnings Details
2/8/2018Q1 2018($0.43)($0.37)$7.48 million$9.32 millionViewN/AView Earnings Details
11/16/2017Q4 2017($0.43)($0.36)$9.57 million$9.44 millionViewN/AView Earnings Details
8/3/2017Q3 2017($0.30)($0.43)$8.71 million$8.11 millionViewListenView Earnings Details
5/11/2017Q2 2017($0.3720)($0.42)$6.05 million$7.35 millionViewN/AView Earnings Details
2/13/2017Q1 2017($0.42)($0.46)$8.07 million$7.00 millionViewN/AView Earnings Details
11/21/2016Q4 2016($0.39)($0.42)$9.08 million$7.92 millionViewN/AView Earnings Details
8/4/2016Q3($0.42)($0.34)$8.38 million$10.61 millionViewN/AView Earnings Details
5/10/2016Q2($0.37)($0.47)$8.64 million$6.96 millionViewListenView Earnings Details
2/8/2016Q1($0.35)($0.42)$8.93 million$7.54 millionViewN/AView Earnings Details
11/12/2015Q4($0.4530)($0.42)$9.47 million$9.27 millionViewListenView Earnings Details
7/29/2015Q3($0.3730)($0.33)$10.45 million$10.60 millionViewListenView Earnings Details
5/7/2015Q2 2015($0.35)($0.40)$9.73 million$11.29 millionViewN/AView Earnings Details
2/10/2015Q115($0.29)($0.37)$10.42 million$9.77 millionViewN/AView Earnings Details
11/17/2014Q4 2014($0.32)($0.51)$10.26 million$11.07 millionViewN/AView Earnings Details
8/12/2014Q3 2014($0.17)($0.28)$12.22 million$10.18 millionViewN/AView Earnings Details
5/13/2014Q2 2014($0.18)($0.24)$10.58 million$10.72 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Corium International (NASDAQ:CORI) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Corium International (NASDAQ CORI) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 30.80%
Institutional Ownership Percentage: 95.13%
Insider Trading History for Corium International (NASDAQ:CORI)
Institutional Ownership by Quarter for Corium International (NASDAQ:CORI)

Corium International (NASDAQ CORI) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/18/2018Life Sciences Maste PerceptiveMajor ShareholderBuy510,000$12.54$6,395,400.00View SEC Filing  
1/16/2018Perceptive Advisors LlcMajor ShareholderBuy50,350$11.83$595,640.50View SEC Filing  
11/17/2017Healthcare Master Fun BroadfinMajor ShareholderSell500,000$10.96$5,480,000.00View SEC Filing  
11/2/2017Healthcare Master Fun BroadfinMajor ShareholderSell150,000$11.05$1,657,500.00View SEC Filing  
10/4/2017Healthcare Master Fun BroadfinMajor ShareholderSell218,100$11.01$2,401,281.00View SEC Filing  
8/22/2017Parminder SinghInsiderSell30,415$7.59$230,849.8530,762View SEC Filing  
8/17/2017Parminder SinghInsiderSell32,000$7.61$243,520.00View SEC Filing  
8/17/2017Timothy D. SweemerCAOSell12,012$7.62$91,531.44View SEC Filing  
8/16/2017Timothy D. SweemerCAOSell15,488$7.82$121,116.16View SEC Filing  
7/20/2017Joseph J. SarretInsiderSell2,038$8.95$18,240.10View SEC Filing  
6/30/2017Life Sciences Maste PerceptiveMajor ShareholderBuy301,004$7.71$2,320,740.84View SEC Filing  
5/25/2017Perceptive Advisors LlcMajor ShareholderBuy1,902,400$6.25$11,890,000.00View SEC Filing  
5/19/2016Eric BjerkholtDirectorBuy24,500$3.64$89,180.00View SEC Filing  
5/12/2016David GreenwoodDirectorBuy3,000$3.58$10,740.003,000View SEC Filing  
2/25/2015Peter D StapleCEOBuy3,600$6.99$25,164.00View SEC Filing  
11/24/2014Robert S BreuilCFOBuy4,600$5.38$24,748.00View SEC Filing  
11/21/2014Peter D StapleCEOBuy9,000$5.34$48,060.00View SEC Filing  
8/27/2014Peter D StapleCEOBuy2,578$6.10$15,725.80View SEC Filing  
5/30/2014Peter D StapleCEOBuy7,200$7.04$50,688.00View SEC Filing  
4/8/2014Woodlands Health Venture EssexMajor ShareholderBuy400,000$8.00$3,200,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Corium International (NASDAQ CORI) News Headlines

Source:
DateHeadline
Equities Analysts Offer Predictions for Corium International Incs Q4 2018 Earnings (CORI)Equities Analysts Offer Predictions for Corium International Inc's Q4 2018 Earnings (CORI)
www.americanbankingnews.com - May 23 at 7:14 AM
Corium International Inc (CORI) Expected to Post Quarterly Sales of $6.72 MillionCorium International Inc (CORI) Expected to Post Quarterly Sales of $6.72 Million
www.americanbankingnews.com - May 22 at 2:32 AM
Moving Average Crossover Alert: Corium International, Inc. (CORI)Moving Average Crossover Alert: Corium International, Inc. (CORI)
finance.yahoo.com - May 21 at 9:44 AM
-$0.39 Earnings Per Share Expected for Corium International Inc (CORI) This Quarter-$0.39 Earnings Per Share Expected for Corium International Inc (CORI) This Quarter
www.americanbankingnews.com - May 20 at 7:18 PM
Corium International (CORI) Given Buy Rating at Cantor FitzgeraldCorium International (CORI) Given Buy Rating at Cantor Fitzgerald
www.americanbankingnews.com - May 18 at 5:09 PM
Corium International (CORI) Downgraded to Buy at ValuEngineCorium International (CORI) Downgraded to Buy at ValuEngine
www.americanbankingnews.com - May 17 at 10:56 PM
Corium International (CORI) Stock Rating Lowered by Zacks Investment ResearchCorium International (CORI) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - May 17 at 8:08 PM
Jefferies Group Equities Analysts Increase Earnings Estimates for Corium International (CORI)Jefferies Group Equities Analysts Increase Earnings Estimates for Corium International (CORI)
www.americanbankingnews.com - May 17 at 8:11 AM
Corium International Forecasted to Earn FY2022 Earnings of $0.67 Per Share (CORI)Corium International Forecasted to Earn FY2022 Earnings of $0.67 Per Share (CORI)
www.americanbankingnews.com - May 16 at 8:20 AM
Corium International (CORI) Q2 2018 Earnings Conference Call TranscriptCorium International (CORI) Q2 2018 Earnings Conference Call Transcript
www.fool.com - May 15 at 2:42 PM
Corium International (CORI) Given a $14.00 Price Target by HC Wainwright AnalystsCorium International (CORI) Given a $14.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - May 15 at 2:25 PM
BRIEF-Corium International Reports Q2 Revenue $10.1 MlnBRIEF-Corium International Reports Q2 Revenue $10.1 Mln
www.reuters.com - May 15 at 10:36 AM
Corium Internationals (CORI) CEO Peter Staple on Q2 2018 Results - Earnings Call TranscriptCorium International's (CORI) CEO Peter Staple on Q2 2018 Results - Earnings Call Transcript
seekingalpha.com - May 15 at 10:36 AM
Corium Reports Second Quarter Fiscal 2018 Financial Results and Corporate HighlightsCorium Reports Second Quarter Fiscal 2018 Financial Results and Corporate Highlights
finance.yahoo.com - May 15 at 10:36 AM
Edited Transcript of CORI earnings conference call or presentation 14-May-18 9:00pm GMTEdited Transcript of CORI earnings conference call or presentation 14-May-18 9:00pm GMT
finance.yahoo.com - May 15 at 10:36 AM
Corium: Fiscal 2Q Earnings SnapshotCorium: Fiscal 2Q Earnings Snapshot
finance.yahoo.com - May 15 at 10:36 AM
Corium International (CORI) Posts Quarterly  Earnings Results, Misses Expectations By $0.04 EPSCorium International (CORI) Posts Quarterly Earnings Results, Misses Expectations By $0.04 EPS
www.americanbankingnews.com - May 15 at 8:28 AM
Corium International (CORI) to Release Quarterly Earnings on MondayCorium International (CORI) to Release Quarterly Earnings on Monday
www.americanbankingnews.com - May 12 at 8:14 PM
Corium International (CORI) Raised to "Hold" at Zacks Investment ResearchCorium International (CORI) Raised to "Hold" at Zacks Investment Research
www.americanbankingnews.com - May 11 at 8:33 PM
Corium International (CORI) Lowered to Sell at BidaskClubCorium International (CORI) Lowered to Sell at BidaskClub
www.americanbankingnews.com - May 10 at 12:36 AM
Corium to Report Second Quarter Fiscal 2018 Financial Results on Monday, May 14, 2018Corium to Report Second Quarter Fiscal 2018 Financial Results on Monday, May 14, 2018
finance.yahoo.com - May 8 at 9:48 AM
Corium International (CORI) Given Average Recommendation of "Buy" by BrokeragesCorium International (CORI) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - May 6 at 7:39 PM
Corium International (CORI) Expected to Announce Quarterly Sales of $7.07 MillionCorium International (CORI) Expected to Announce Quarterly Sales of $7.07 Million
www.americanbankingnews.com - May 5 at 3:57 AM
ValuEngine Upgrades Corium International (CORI) to "Strong-Buy"ValuEngine Upgrades Corium International (CORI) to "Strong-Buy"
www.americanbankingnews.com - May 3 at 8:25 PM
Corium International (CORI) Expected to Post Earnings of -$0.41 Per ShareCorium International (CORI) Expected to Post Earnings of -$0.41 Per Share
www.americanbankingnews.com - May 3 at 9:22 AM
Corium International (CORI) Expected to Post Quarterly Sales of $7.07 MillionCorium International (CORI) Expected to Post Quarterly Sales of $7.07 Million
www.americanbankingnews.com - April 18 at 4:14 AM
Corium International (CORI) Cut to Sell at Zacks Investment ResearchCorium International (CORI) Cut to Sell at Zacks Investment Research
www.americanbankingnews.com - April 16 at 8:40 PM
Corium International (CORI) Rating Lowered to Buy at BidaskClubCorium International (CORI) Rating Lowered to Buy at BidaskClub
www.americanbankingnews.com - April 16 at 10:55 AM
Zacks: Brokerages Expect Corium International (CORI) to Post -$0.41 Earnings Per ShareZacks: Brokerages Expect Corium International (CORI) to Post -$0.41 Earnings Per Share
www.americanbankingnews.com - April 16 at 7:11 AM
Corium International (CORI) Downgraded by BidaskClubCorium International (CORI) Downgraded by BidaskClub
www.americanbankingnews.com - April 13 at 4:55 PM
Why the Earnings Streak Will Continue for Corium International (CORI)Why the Earnings Streak Will Continue for Corium International (CORI)
finance.yahoo.com - April 13 at 10:26 AM
CymaBay Therapeutics (CBAY) in Focus: Stock Moves 11.4% HigherCymaBay Therapeutics (CBAY) in Focus: Stock Moves 11.4% Higher
finance.yahoo.com - April 12 at 10:56 AM
Corium International (CORI) Receives Average Recommendation of "Buy" from BrokeragesCorium International (CORI) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - April 11 at 5:43 PM
Zacks Investment Research Lowers Corium International (CORI) to HoldZacks Investment Research Lowers Corium International (CORI) to Hold
www.americanbankingnews.com - April 5 at 8:30 PM
Corium International (CORI) Given a $10.00 Price Target by Jefferies Group AnalystsCorium International (CORI) Given a $10.00 Price Target by Jefferies Group Analysts
www.americanbankingnews.com - April 4 at 4:42 PM
Corium International (CORI) Lifted to "Buy" at ValuEngineCorium International (CORI) Lifted to "Buy" at ValuEngine
www.americanbankingnews.com - April 3 at 5:52 PM
Corium International (CORI) Upgraded to Buy by Zacks Investment ResearchCorium International (CORI) Upgraded to Buy by Zacks Investment Research
www.americanbankingnews.com - April 2 at 8:40 PM
Corium International (CORI) Upgraded to "Hold" at ValuEngineCorium International (CORI) Upgraded to "Hold" at ValuEngine
www.americanbankingnews.com - March 31 at 3:20 PM
Corium International (CORI) Downgraded by Zacks Investment Research to HoldCorium International (CORI) Downgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - March 30 at 8:23 PM
Corium International (CORI) Expected to Announce Earnings of -$0.41 Per ShareCorium International (CORI) Expected to Announce Earnings of -$0.41 Per Share
www.americanbankingnews.com - March 30 at 9:22 AM
Corium International (CORI) Sees Significant Growth in Short InterestCorium International (CORI) Sees Significant Growth in Short Interest
www.americanbankingnews.com - March 30 at 3:38 AM
Cantor Fitzgerald Reiterates Buy Rating for Corium International (CORI)Cantor Fitzgerald Reiterates Buy Rating for Corium International (CORI)
www.americanbankingnews.com - March 27 at 9:10 PM
Corium International (CORI) Rating Increased to Buy at BidaskClubCorium International (CORI) Rating Increased to Buy at BidaskClub
www.americanbankingnews.com - March 26 at 11:30 PM
Corium International (CORI) Upgraded to "Hold" by ValuEngineCorium International (CORI) Upgraded to "Hold" by ValuEngine
www.americanbankingnews.com - March 25 at 7:32 PM
Corium International (CORI) Cut to "Hold" at Zacks Investment ResearchCorium International (CORI) Cut to "Hold" at Zacks Investment Research
www.americanbankingnews.com - March 23 at 8:28 PM
Corium International (CORI) Stock Rating Upgraded by Zacks Investment ResearchCorium International (CORI) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - March 22 at 8:42 PM
Corium to Present at the 17th Annual Needham Healthcare ConferenceCorium to Present at the 17th Annual Needham Healthcare Conference
globenewswire.com - March 20 at 10:07 AM
Corium to Present at the 17th Annual Needham Healthcare Conference Corium to Present at the 17th Annual Needham Healthcare Conference 
finance.yahoo.com - March 19 at 10:08 AM
Corium International (CORI) Cut to "Hold" at BidaskClubCorium International (CORI) Cut to "Hold" at BidaskClub
www.americanbankingnews.com - March 18 at 7:10 PM
Corium International Inc (CORI) Receives Average Recommendation of "Buy" from BrokeragesCorium International Inc (CORI) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - March 17 at 5:30 PM

SEC Filings

Corium International (NASDAQ:CORI) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Corium International (NASDAQ:CORI) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Corium International (NASDAQ CORI) Stock Chart for Thursday, May, 24, 2018

Loading chart…

This page was last updated on 5/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.